Related Experiment Video
Updated: Jun 20, 2026

Pharmacologic Induction of Epidermal Melanin and Protection Against Sunburn in a Humanized Mouse Model
Published on: September 7, 2013
Cutaneous pigmentation after photosensitivity induced by vandetanib therapy
Heidi H Kong1, Howard A Fine, Jere B Stern
1Dermatology Branch, Center for Cancer Research, National Cancer Institute, Bldg 10, Room 12N238, 10 Center Dr, Bethesda, MD 20892, USA. konghe@mail.nih.gov
Background:
Photosensitivity has been reported in patients who were treated with vandetanib (ZD6474), an inhibitor of epidermal growth factor receptor, vascular endothelial growth factor receptor, and the RET (rearranged during transfection) kinases.
Observations:
We describe the occurrence of cutaneous hyperpigmentation after photosensitivity in 2 patients who were treated with vandetanib. The pigmentation patterns were variable within and between patients. Biopsy specimens from different sites revealed variability in Perls and Fontana staining patterns.
Conclusions:
These 2 cases highlight the unusual occurrence of cutaneous hyperpigmentation after vandetanib-associated photosensitivity, a reaction that demonstrates that medications are important causes of acquired photosensitivity and hyperpigmentation. Aggressive photoprotection may facilitate the resolution of diffuse hyperpigmentation. Dermatologists should endeavor to identify and report novel cutaneous adverse effects as new targeted therapies are developed.
Insights
Vandetanib treatment can cause skin hyperpigmentation following photosensitivity. Early photoprotection may help resolve this unusual drug-induced skin reaction.
Area of Science:
- Dermatology
- Oncology
- Pharmacology
Background:
- Vandetanib, a multi-targeted tyrosine kinase inhibitor, is used in cancer therapy.
- Photosensitivity is a known adverse effect of vandetanib treatment.
Observation:
- Two patients developed cutaneous hyperpigmentation after experiencing photosensitivity to vandetanib.
- Variable pigmentation patterns were observed within and between patients.
- Biopsies showed inconsistent Perls and Fontana staining, indicating complex melanin deposition.
Findings:
- Vandetanib can induce both photosensitivity and subsequent cutaneous hyperpigmentation.
- The observed hyperpigmentation exhibited significant variability in presentation.
Implications:
- This highlights acquired photosensitivity and hyperpigmentation as potential adverse effects of targeted therapies.
- Dermatologists should recognize and report such reactions to new drugs.
- Aggressive photoprotection is recommended for managing diffuse hyperpigmentation.
Related Concept Videos
Pigmentation
Melanin occurs in two primary forms: eumelanin that provides black and brown pigment and pheomelanin that provides red color. Dark-skinned individuals produce more melanin than those with pale...
Changes in Skin Color: Clinical Perspectives
Albinism
Albinism is a genetic disorder that affects (completely or partially) the coloring of skin, hair, and eyes. The defect is primarily...
Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Role of Skin in Vitamin D Synthesis
The solar UV B rays (290-315 nm) are absorbed by the skin, and 7-dehydrocholesterol (provitamin D3) photolyzes it to previtamin D3, which undergoes a rapid transformation to vitamin D3(cholecalciferol).
Skin Diseases and Disorders
Gram-positive Staphylococcus spp. and Streptococcus spp. are responsible for many of the most common skin infections. However, many...
Drug Toxicity: Allergic Reactions
